Formulation
DC
First Claim
1. A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of from 10 to 30% weight of ethanol and benzyl alcohol per volume of formulation and 10 to 25% weight of benzyl benzoate per volume of formulation and a sufficient amount of a castor oil vehicle, whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml−
- 1 is attained for at least 2 weeks after injection.
1 Assignment
Litigations
1 Petition
Accused Products
Abstract
The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
34 Citations
12 Claims
-
1. A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of from 10 to 30% weight of ethanol and benzyl alcohol per volume of formulation and 10 to 25% weight of benzyl benzoate per volume of formulation and a sufficient amount of a castor oil vehicle, whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml−
- 1 is attained for at least 2 weeks after injection.
- View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
2. A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of from 10 to 30% weight of a mixture of ethanol and benzyl alcohol per volume of formulation and from 10 to 25% weight of benzyl benzoate per volume of formulation and a sufficient amount of a castor oil vehicle, whereby the formulation comprises at least 45 mgml−
- 1 of fulvestrant.
Specification
-
- Resources
-
Current AssigneeAstrazeneca AB (Astrazeneca PLC)
-
Original AssigneeAstrazeneca AB (Astrazeneca PLC)
-
InventorsGrundy, Rosalind U, Evans, John R
-
Primary Examiner(s)HUI, SAN MING R
-
Application NumberUS10/872,784Publication NumberTime in Patent Office1,617 DaysField of SearchNoneUS Class Current514/177CPC Class CodesA61K 31/565 not substituted in position...A61K 47/10 Alcohols; Phenols; Salts th...A61K 47/14 Esters of carboxylic acids,...A61K 47/44 Oils, fats or waxes accordi...A61K 9/0019 Injectable compositions; In...A61P 15/00 Drugs for genital or sexual...A61P 35/00 Antineoplastic agentsA61P 43/00 Drugs for specific purposes...A61P 5/24 of the sex hormonesA61P 5/32 Antioestrogens
